Portal de Periódicos da CAPES

Melatonin reduces lead levels in blood, brain and bone and increases lead excretion in rats subjected to subacute lead treatment

2015; Elsevier BV; Volume: 233; Issue: 2 Linguagem: Inglês

10.1016/j.toxlet.2015.01.009

1879-3169

Everardo Hernández‐Plata, Fátima Quiroz-Compeán, Gonzalo Ramírez‐García, Eunice Yáñez Barrientos, Nadia M. Rodríguez-Morales, Alberto Flores, Katarzyna Wróbel, Kazimierz Wróbel, Isabel García Méndez, Mauricio Díaz‐Muñoz, Juvencio Robles, Minerva Martínez‐Alfaro,

Heavy metals in environment

Melatonin, a hormone known for its effects on free radical scavenging and antioxidant activity, can reduce lead toxicity in vivo and in vitro.We examined the effects of melatonin on lead bio-distribution. Rats were intraperitoneally injected with lead acetate (10, 15 or 20 mg/kg/day) with or without melatonin (10 mg/kg/day) daily for 10 days. In rats intoxicated with the highest lead doses, those treated with melatonin had lower lead levels in blood and higher levels in urine and feces than those treated with lead alone, suggesting that melatonin increases lead excretion. To explore the mechanism underlying this effect, we first assessed whether lead/melatonin complexes were formed directly. Electronic density functional (DFT) calculations showed that a lead/melatonin complex is energetically feasible; however, UV spectroscopy and NMR analysis showed no evidence of such complexes. Next, we examined the liver mRNA levels of metallothioneins (MT) 1 and 2. Melatonin cotreatment increased the MT2 mRNA expression in the liver of rats that received the highest doses of lead. The potential effects of MTs on the tissue distribution and excretion of lead are not well understood. This is the first report to suggest that melatonin directly affects lead levels in organisms exposed to subacute lead intoxication.